Mesa Laboratories Net Income From Continuing Ops Over Time
| MLAB Stock | USD 79.80 0.00 0.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Mesa Laboratories Performance and Mesa Laboratories Correlation. Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesa Laboratories. Expected growth trajectory for Mesa significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Mesa Laboratories assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.29) | Dividend Share 0.64 | Earnings Share (0.31) | Revenue Per Share | Quarterly Revenue Growth 0.05 |
The market value of Mesa Laboratories is measured differently than its book value, which is the value of Mesa that is recorded on the company's balance sheet. Investors also form their own opinion of Mesa Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Mesa Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesa Laboratories' market value can be influenced by many factors that don't directly affect Mesa Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Mesa Laboratories' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mesa Laboratories represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Mesa Laboratories' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare Mesa Laboratories and related stocks such as LightPath Technologies, Microvision, and Vishay Precision Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LPTH | (864.9 K) | (864.9 K) | 215.3 K | (313.2 K) | (715.3 K) | 1.4 M | 7.7 M | 1.1 M | (2.7 M) | 866.9 K | (3.2 M) | (3.5 M) | (4 M) | (8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| MVIS | (35.8 M) | (35.8 M) | (22.7 M) | (13.2 M) | (18.1 M) | (14.5 M) | (16.5 M) | (24.2 M) | (27.2 M) | (26.5 M) | (13.6 M) | (43.2 M) | (53.1 M) | (76.6 M) | (96.9 M) | (87.2 M) | (82.9 M) |
| VPG | 10.8 M | 10.8 M | 11.8 M | 4.3 M | 4 M | (13 M) | 6.4 M | 14.4 M | 23.6 M | 22.3 M | 10.8 M | 20.4 M | 36.6 M | 30.5 M | 9.8 M | 11.3 M | 15.2 M |
| GRVY | (19.8 B) | (19.8 B) | (19.8 B) | (19.8 B) | (19 M) | (15 M) | 179 M | 13.3 B | 31.4 B | 39.7 B | 88 B | 65.9 B | 83.1 B | 143.7 B | 84.9 B | 97.6 B | 102.5 B |
| PUBM | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 6.6 M | 26.6 M | 56.6 M | 28.7 M | 3 M | 12.5 M | 14.4 M | 21.8 M |
| EGAN | (4.9 M) | (4.9 M) | 684 K | (5.2 M) | (12.4 M) | (6.2 M) | (6 M) | (2 M) | 4.2 M | 7.2 M | 7 M | (2.4 M) | 2.1 M | 7.8 M | 32.3 M | 37.1 M | 38.9 M |
| GDEV | (35.5 M) | (35.5 M) | (35.5 M) | (35.5 M) | (35.5 M) | (35.5 M) | (35.5 M) | (35.5 M) | (35.5 M) | (35.5 M) | (751 K) | (117.4 M) | 7.4 M | (41.9 M) | 25.5 M | 29.4 M | 30.8 M |
| GRRR | (535.9 K) | (535.9 K) | (535.9 K) | (535.9 K) | (535.9 K) | (535.9 K) | (535.9 K) | (535.9 K) | (535.9 K) | (535.9 K) | (5.9 M) | (8.5 M) | (87.5 M) | 13.5 M | (64.8 M) | (58.3 M) | (55.4 M) |
| XRX | 1.1 B | 1.1 B | 1.1 B | 1.1 B | 1.1 B | 840 M | 627 M | 204 M | 374 M | 651 M | 192 M | (455 M) | (322 M) | 182 M | (1.3 B) | (1.2 B) | (1.1 B) |
| BZAI | (104.6 M) | (104.6 M) | (104.6 M) | (104.6 M) | (104.6 M) | (104.6 M) | (104.6 M) | (104.6 M) | (104.6 M) | (104.6 M) | (104.6 M) | (104.6 M) | (104.6 M) | 1.3 M | (4.1 M) | (4.7 M) | (5 M) |
Mesa Laboratories and related stocks such as LightPath Technologies, Microvision, and Vishay Precision Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Mesa Laboratories | MLAB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 12100 West Sixth |
| Exchange | NASDAQ Exchange |
USD 79.8
Check out Mesa Laboratories Performance and Mesa Laboratories Correlation. For information on how to trade Mesa Stock refer to our How to Trade Mesa Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Mesa Laboratories technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.